Identification of Drug-Disease Associations by Using Multiple Drug and Disease Networks

被引:62
|
作者
Yang, Ying [1 ]
Chen, Lei [1 ]
机构
[1] Shanghai Maritime Univ, Coll Informat Engn, Shanghai 201306, Peoples R China
关键词
Drug repositioning; drug-disease association; network embedding method; random forest; mashup; classic classifi-; cation algorithm; RANDOM-WALK; PRIORITIZATION; INTEGRATION;
D O I
10.2174/1574893616666210825115406
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background: Drug repositioning is a new research area in drug development. It aims to discover novel therapeutic uses of existing drugs. It could accelerate the process of designing novel drugs for some diseases and considerably decrease the cost. The traditional method to determine novel therapeutic uses of an existing drug is quite laborious. It is alternative to design computational methods to overcome such defect. Objective: This study aims to propose a novel model for the identification of drug-disease associations. Methods: Twelve drug networks and three disease networks were built, which were fed into a powerful network-embedding algorithm called Mashup to produce informative drug and disease features. These features were combined to represent each drug-disease association. Classic classification algorithm, random forest, was used to build the model. Results: Tenfold cross-validation results indicated that the MCC, AUROC, and AUPR were 0.7156, 0.9280, and 0.9191, respectively. Conclusion: The proposed model showed good performance. Some tests indicated that a small dimension of drug features and a large dimension of disease features were beneficial for constructing the model. Moreover, the model was quite robust even if some drug or disease properties were not available.
引用
下载
收藏
页码:48 / 59
页数:12
相关论文
共 50 条
  • [31] A miRNA-Driven Inference Model to Construct Potential Drug-Disease Associations for Drug Repositioning
    Chen, Hailin
    Zhang, Zuping
    BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [32] Comparing Drug-Disease Associations in Clinical Practice Guideline Recommendations and Drug Product Label Indications
    Leung, Tiffany I.
    Dumontier, Michel
    MEDINFO 2015: EHEALTH-ENABLED HEALTH, 2015, 216 : 1039 - 1039
  • [33] DRUG-DRUG AND DRUG-DISEASE INTERACTIONS WITH NONSTEROIDAL ANTIINFLAMMATORY DRUGS
    JEFFERSON, JW
    GREIST, JH
    CARROLL, J
    BAUDHUIN, M
    AMERICAN JOURNAL OF MEDICINE, 1986, 81 (05): : 948 - 948
  • [34] DRUG-DRUG AND DRUG-DISEASE INTERACTIONS WITH NONSTEROIDAL ANTIINFLAMMATORY DRUGS
    BRATER, DC
    AMERICAN JOURNAL OF MEDICINE, 1986, 80 (1A): : 62 - 77
  • [35] Drug-Disease Interactions: Assessment by Disease State.
    Pugh, M. V.
    Starner, C.
    Berlowitz, D.
    Hanlon, J.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2010, 58 : 148 - 148
  • [36] DRUG-DISEASE INTERACTIONS - A REVIEW OF THE LITERATURE
    GIDUMAL, R
    KUPERSMITH, J
    MOUNT SINAI JOURNAL OF MEDICINE, 1981, 48 (01): : 7 - 20
  • [37] Prediction of Potential Drug-Disease Associations through Deep Integration of Diversity and Projections of Various Drug Features
    Xuan, Ping
    Song, Yingying
    Zhang, Tiangang
    Jia, Lan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (17)
  • [38] Predicting drug-disease associations through layer attention graph convolutional network
    Yu, Zhouxin
    Huang, Feng
    Zhao, Xiaohan
    Xiao, Wenjie
    Zhang, Wen
    BRIEFINGS IN BIOINFORMATICS, 2021, 22 (04)
  • [39] A model for predicting drug-disease associations based on dense convolutional attention network
    Wang, Huiqing
    Zhao, Sen
    Zhao, Jing
    Feng, Zhipeng
    MATHEMATICAL BIOSCIENCES AND ENGINEERING, 2021, 18 (06) : 7419 - 7439
  • [40] Overlap in drug-disease associations between clinical practice guidelines and drug structured product label indications
    Tiffany I. Leung
    Michel Dumontier
    Journal of Biomedical Semantics, 7